Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q2 2012 | Q2 2011 |
|---|---|---|
| Revenue | $91.00K | $750.00K |
| Net Income | -$10.01M | -$7.38M |
| EPS Diluted | -$0.61 | -$6.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
